logo
  

Veeco Instruments Posts Narrower Than Estimated Q3 Loss

Veeco Instruments Inc. (VECO) reported a net loss for the third quarter of $14.0 million or $0.35 per share, compared to a net loss of $6.0 million or $0.16 per share for the year-ago quarter.

Excluding items, adjusted net loss for the third quarter was $0.8 million or $0.02 per share, compared to an adjusted net loss of $3.0 million or $0.08 per share in the prior year quarter.

Revenue for the third quarter fell to $93.3 million from $99.3 million a year ago.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.12 per share on revenue of $96.63 million for the third quarter. Analysts' estimates typically exclude special items.

Looking forward to the fourth quarter, the company forecasts revenue of $100 million to $115 million, loss of $0.25 to $0.13 per share. The company's fourth quarter adjusted results are expected between a loss $0.03 per share and profit of $0.09 per share. Analysts currently expect the company to earn $0.01 per share on revenue of $108.58 million for the fourth quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT